Literature DB >> 18769027

Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy.

Kazuro Ikawa1, Norifumi Morikawa, Kayo Ikeda, Hiroki Ohge, Taijiro Sueda, Hidemichi Suyama, Masao Doi, Masao Kuwabara.   

Abstract

BACKGROUND: A pharmacokinetic-pharmacodynamic (PK-PD) target attainment analysis to build a dosing strategy for biapenem in adult patients has not been conducted.
METHODS: A total of 321 plasma concentration samples from 68 adult patients (1-6 samples per patient) were assayed biologically and chromatographically, and used for a population PK modeling and Monte Carlo simulation to assess the probability of attaining the PK-PD target (40% of the time above the minimum inhibitory concentration).
RESULTS: The population PK model was based on the standard two-compartment model, and creatinine clearance (Cl(cr)) was the most significant covariate that affected the drug clearance. The Monte Carlo simulation demonstrated that the dosages up to 600 mg Q12H (0.5-h infusions) achieved a PK-PD target attainment probability of > or =90%, which varied with Cl(cr) of the patient and susceptibility of the tested bacterium; however, higher dosage with prolonged infusion time (600 mg Q8H, 3 h infusion) was required for a high probability against Pseudomonas aeruginosa and Haemophilus influenzae isolates in the case of Cl(cr) = 90 ml/min.
CONCLUSION: These results provide guidance for constructing a PK-PD-based strategy for tailoring biapenem regimens in adult patients. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769027     DOI: 10.1159/000152459

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

Review 1.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

2.  Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.

Authors:  Kazuro Ikawa; Akira Nakashima; Norifumi Morikawa; Kayo Ikeda; Yoshiaki Murakami; Hiroki Ohge; Hartmut Derendorf; Taijiro Sueda
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

3.  In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Authors:  Amit Kaushik; Nicole C Ammerman; Rokeya Tasneen; Elizabeth Story-Roller; Kelly E Dooley; Susan E Dorman; Eric L Nuermberger; Gyanu Lamichhane
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.